Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with valines and intron reservoirs.

Piskacek M, Havelka M, Jendruchova K, Knight A, Keegan LP.

Cell Mol Life Sci. 2019 Aug 2. doi: 10.1007/s00018-019-03251-w. [Epub ahead of print]

PMID:
31375868
2.

Nuclear hormone receptors: Ancient 9aaTAD and evolutionally gained NCoA activation pathways.

Piskacek M, Havelka M, Jendruchova K, Knight A.

J Steroid Biochem Mol Biol. 2019 Mar;187:118-123. doi: 10.1016/j.jsbmb.2018.11.008. Epub 2018 Nov 20.

PMID:
30468856
3.

The 9aaTAD Is Exclusive Activation Domain in Gal4.

Piskacek M, Havelka M, Rezacova M, Knight A.

PLoS One. 2017 Jan 5;12(1):e0169261. doi: 10.1371/journal.pone.0169261. eCollection 2017.

4.

The 9aaTAD Transactivation Domains: From Gal4 to p53.

Piskacek M, Havelka M, Rezacova M, Knight A.

PLoS One. 2016 Sep 12;11(9):e0162842. doi: 10.1371/journal.pone.0162842. eCollection 2016.

5.

Do human B-lymphocytes avoid aging until 60 years?

Knight A, Nemec P, Bretzova S, Valkova L, Kolmanova M, Vytopilova R, Havelka M, Vsianska P, Rihova L, Krejci M, Piskacek M.

Oncotarget. 2016 Jul 12;7(28):42873-42880. doi: 10.18632/oncotarget.10146.

Supplemental Content

Loading ...
Support Center